company background image
BNGO

Bionano Genomics NasdaqCM:BNGO Stock Report

Last Price

US$2.41

Market Cap

US$699.2m

7D

29.6%

1Y

-61.9%

Updated

07 Aug, 2022

Data

Company Financials +
BNGO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BNGO Stock Overview

Bionano Genomics, Inc. provides genome analysis software solutions.

Bionano Genomics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bionano Genomics
Historical stock prices
Current Share PriceUS$2.41
52 Week HighUS$6.37
52 Week LowUS$1.16
Beta2.28
1 Month Change47.85%
3 Month Change75.91%
1 Year Change-61.87%
3 Year Change26.84%
5 Year Changen/a
Change since IPO-65.52%

Recent News & Updates

Aug 04

Bionano stock down ~8% after hours; co reports Q2 revenue beat, wider loss

Shares of small-cap pharmaceutical company Bionano Genomics (NASDAQ:BNGO) fell 8.1% to $2.16 in Thursday postmarket trading, after the genome analysis firm reported a wider Q2 loss and a significant fall in quarterly gross margin. It is worth noting that BNGO stock had gained 27% since Tuesday and posted a three-day winning streak at today's close. BNGO announced Q2 net loss of $32.16M compared to a loss of $18.79M last year. However, its revenue of $6.67M grew a healthy 72.8% Y/Y and beat estimates by $0.39M. The company said the quarterly figure was an all-time high for it. Revenue growth was aided by expansion of the installed base of BNGO's Saphyr sytems and a 24% Y/Y rise in sales of nanochannel array flowcells. The company's bottom line was hurt due to a 87.2% Y/Y rise in total operating expenses to $33.55M. BNGO CEO Erik Holmlin said that the company remained on track to achieve its previously outlined ELEVATE! milestones for the second half of the year. Bionano Geonomics (BNGO) stock has lost 21.4% YTD.

Jun 29

Bionano gets US patent for analysis of nucleic acid fragments for genetic abnormalities

Bionano Genomics (NASDAQ:BNGO) said the U.S. Patent and Trademark Office issued a patent related to methods claiming the use of certain nanochannel arrays to detect and quantitate genetic abnormalities. The U.S. patent No.11,359,244 titled Characterization of Molecules in Nanofluidics, claims methods for analyzing small nucleic acid fragments in nanochannel arrays, which Bionano has used to analyze ultra-high molecular weight (UHMW) DNA for the identification of structural variants (SVs) as part of its Saphyr system, the company said in a June 29 press release. Bionano added the methods claim the use of certain nanochannel arrays to detect and quantitate genetic abnormalities, including a DNA translocation, amplification, inversion, and sex chromosome aneuploidy, among other things. The company said it believes that the methods in the patent may one day support the commercialization of assays directed to non-invasive prenatal testing (NIPT) in maternal fetal medicine or ctDNA in oncology. BNGO +2.11% to $1.45 premarket June 29

Shareholder Returns

BNGOUS Life SciencesUS Market
7D29.6%-0.7%1.0%
1Y-61.9%-20.5%-12.9%

Return vs Industry: BNGO underperformed the US Life Sciences industry which returned -20.5% over the past year.

Return vs Market: BNGO underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is BNGO's price volatile compared to industry and market?
BNGO volatility
BNGO Average Weekly Movement14.7%
Life Sciences Industry Average Movement11.1%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: BNGO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: BNGO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2003299Robert Holmlinhttps://www.bionanogenomics.com

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.

Bionano Genomics Fundamentals Summary

How do Bionano Genomics's earnings and revenue compare to its market cap?
BNGO fundamental statistics
Market CapUS$699.24m
Earnings (TTM)-US$105.81m
Revenue (TTM)US$23.32m

30.0x

P/S Ratio

-6.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BNGO income statement (TTM)
RevenueUS$23.32m
Cost of RevenueUS$19.60m
Gross ProfitUS$3.72m
Other ExpensesUS$109.54m
Earnings-US$105.81m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.36
Gross Margin15.97%
Net Profit Margin-453.69%
Debt/Equity Ratio0%

How did BNGO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BNGO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BNGO?

Other financial metrics that can be useful for relative valuation.

BNGO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue22.4x
Enterprise Value/EBITDA-5.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BNGO's PS Ratio compare to its peers?

BNGO PS Ratio vs Peers
The above table shows the PS ratio for BNGO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.3x
QTRX Quanterix
5.7x22.4%US$644.8m
CDXS Codexis
4.2x11.0%US$573.1m
NSTG NanoString Technologies
5x24.0%US$716.0m
ADPT Adaptive Biotechnologies
10.2x22.5%US$1.6b
BNGO Bionano Genomics
30x59.7%US$699.2m

Price-To-Sales vs Peers: BNGO is expensive based on its Price-To-Sales Ratio (30x) compared to the peer average (6.3x).


Price to Earnings Ratio vs Industry

How does BNGO's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Sales vs Industry: BNGO is expensive based on its Price-To-Sales Ratio (30x) compared to the US Life Sciences industry average (5.3x)


Price to Sales Ratio vs Fair Ratio

What is BNGO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BNGO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30x
Fair PS Ratio14.6x

Price-To-Sales vs Fair Ratio: BNGO is expensive based on its Price-To-Sales Ratio (30x) compared to the estimated Fair Price-To-Sales Ratio (14.6x).


Share Price vs Fair Value

What is the Fair Price of BNGO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BNGO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BNGO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Bionano Genomics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


31.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BNGO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BNGO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BNGO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BNGO's revenue (59.7% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: BNGO's revenue (59.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BNGO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Bionano Genomics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-38.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BNGO is currently unprofitable.

Growing Profit Margin: BNGO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BNGO is unprofitable, and losses have increased over the past 5 years at a rate of 38.7% per year.

Accelerating Growth: Unable to compare BNGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNGO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (15.9%).


Return on Equity

High ROE: BNGO has a negative Return on Equity (-37.16%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Bionano Genomics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BNGO's short term assets ($216.3M) exceed its short term liabilities ($27.9M).

Long Term Liabilities: BNGO's short term assets ($216.3M) exceed its long term liabilities ($8.9M).


Debt to Equity History and Analysis

Debt Level: BNGO is debt free.

Reducing Debt: BNGO currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BNGO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BNGO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 34.5% each year.


Discover healthy companies

Dividend

What is Bionano Genomics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BNGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BNGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BNGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNGO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BNGO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Robert Holmlin (54 yo)

11.58yrs

Tenure

US$7,580,471

Compensation

Dr. Robert Erik Holmlin, Ph D., M.B.A. has been the Chief Executive Officer and President of BioNano Genomics, Inc. (alternatively BioNanomatrix, Inc.) since January 12, 2011 and serves as its Secretary. D...


CEO Compensation Analysis

Compensation vs Market: Robert's total compensation ($USD7.58M) is above average for companies of similar size in the US market ($USD3.94M).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BNGO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: BNGO's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BNGO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.


Top Shareholders

Company Information

Bionano Genomics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Bionano Genomics, Inc.
  • Ticker: BNGO
  • Exchange: NasdaqCM
  • Founded: 2003
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$699.237m
  • Shares outstanding: 290.14m
  • Website: https://www.bionanogenomics.com

Number of Employees


Location

  • Bionano Genomics, Inc.
  • 9540 Towne Centre Drive
  • Suite 100
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.